Advertisement

Perioperative Care of the Orthopedic Patient with Connective Tissue Disease

  • Susan M. GoodmanEmail author
Chapter
  • 22 Downloads

Abstract

Patients with connective tissue diseases and inflammatory arthritis frequently require orthopedic surgery in the setting of poorly responsive inflammatory arthritis or osteonecrosis. Multisystem involvement in these patients may include cardiopulmonary disease that should be investigated preoperatively. Results of surgery are gratifying specifically with respect to pain relief, but functional improvements may lag behind patients with osteoarthritis undergoing the same procedures. Careful collaboration between surgeons, anesthesiologists, and rheumatologists is fundamental in order to optimize outcome.

Keywords

Total hip arthroplasty Total knee arthroplasty Rheumatoid arthritis Systemic lupus Spondyloarthritis 

References

  1. 1.
    Urban MK, Jules-Elysee K, Loughlin C, Kelsey W, Flynn E. The one year incidence of postoperative myocardial infarction in an orthopedic population. HSS J. 2008;4(1):76–80.PubMedCrossRefGoogle Scholar
  2. 2.
    Pincus T, Sokka T, Kautiainen H. Patients seen for standard rheumatoid arthritis care have significantly better articular, radiographic, laboratory, and functional status in 2000 than in 1985. Arthritis Rheum. 2005;52(4):1009–19.PubMedCrossRefGoogle Scholar
  3. 3.
    Massardo L, Gabriel SE, Crowson CS, O’Fallon WM, Matteson EL. A population based assessment of the use of orthopedic surgery in patients with rheumatoid arthritis. J Rheumatol. 2002;29(1):52–6.PubMedGoogle Scholar
  4. 4.
    Wolfe F, Zwillich SH. The long-term outcomes of rheumatoid arthritis: a 23-year prospective, longitudinal study of total joint replacement and its predictors in 1,600 patients with rheumatoid arthritis. Arthritis Rheum. 1998;41(6):1072–82.PubMedCrossRefGoogle Scholar
  5. 5.
    Weiss RJ, Ehlin A, Montgomery SM, Wick MC, Stark A, Wretenberg P. Decrease of RA-related orthopaedic surgery of the upper limbs between 1998 and 2004: data from 54,579 Swedish RA inpatients. Rheumatology (Oxford). 2008;47(4):491–4.CrossRefGoogle Scholar
  6. 6.
    Weiss RJ, Stark A, Wick MC, Ehlin A, Palmblad K, Wretenberg P. Orthopaedic surgery of the lower limbs in 49,802 rheumatoid arthritis patients: results from the Swedish National Inpatient Registry during 1987 to 2001. Ann Rheum Dis. 2006;65(3):335–41.PubMedCrossRefGoogle Scholar
  7. 7.
    Nikiphorou E, Carpenter L, Morris S, Macgregor AJ, Dixey J, Kiely P, et al. Hand and foot surgery rates in rheumatoid arthritis have declined from 1986 to 2011, but large-joint replacement rates remain unchanged: results from two UK inception cohorts. Arthritis Rheumatol. 2014;66(5):1081–9.PubMedCrossRefGoogle Scholar
  8. 8.
    Mertelsmann-Voss C, Lyman S, Pan TJ, Goodman SM, Figgie MP, Mandl LA. US trends in rates of arthroplasty for inflammatory arthritis including rheumatoid arthritis, juvenile idiopathic arthritis, and spondyloarthritis. Arthritis Rheumatol. 2014;66(6):1432–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Fleisher LA, Beckman JA, Brown KA, Calkins H, Chaikof EL, Fleischmann KE, et al. ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery) Developed in Collaboration With the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery. J Am Coll Cardiol. 2007;50(17):1707–32.PubMedCrossRefGoogle Scholar
  10. 10.
    Domsic RT, Lingala B, Krishnan E. Systemic lupus erythematosus, rheumatoid arthritis, and postarthroplasty mortality: a cross-sectional analysis from the nationwide inpatient sample. J Rheumatol. 2010;37(7):1467–72.PubMedCrossRefGoogle Scholar
  11. 11.
    Salmon JE, Roman MJ. Subclinical atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus. Am J Med. 2008;121(10 Suppl 1):S3–8.PubMedPubMedCentralCrossRefGoogle Scholar
  12. 12.
    Roman MJ, Shanker BA, Davis A, Lockshin MD, Sammaritano L, Simantov R, et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med. 2003;349(25):2399–406.PubMedCrossRefGoogle Scholar
  13. 13.
    Mathieu S, Gossec L, Dougados M, Soubrier M. Cardiovascular profile in ankylosing spondylitis. A systematic review and metaanalysis. Arthritis Care Res (Hoboken). 2011;63(4):557–63.CrossRefGoogle Scholar
  14. 14.
    McCarey D, Sturrock RD. Comparison of cardiovascular risk in ankylosing spondylitis and rheumatoid arthritis. Clin Exp Rheumatol. 2009;27(4 Suppl 55):S124–6.PubMedGoogle Scholar
  15. 15.
    Gladman DD. Mortality in psoriatic arthritis. Clin Exp Rheumatol. 2008;26(5 Suppl 51):S62–5.PubMedGoogle Scholar
  16. 16.
    Gladman DD, Ang M, Su L, Tom BD, Schentag CT, Farewell VT. Cardiovascular morbidity in psoriatic arthritis. Ann Rheum Dis. 2009;68(7):1131–5.PubMedCrossRefGoogle Scholar
  17. 17.
    Greenberg JD, Kremer JM, Curtis JR, Hochberg MC, Reed G, Tsao P, et al. Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70(4):576–82.PubMedCrossRefGoogle Scholar
  18. 18.
    Naranjo A, Sokka T, Descalzo MA, Calvo-Alen J, Horslev-Petersen K, Luukkainen RK, et al. Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthritis Res Ther. 2008;10(2):R30.PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    van Eijk IC, de Vries MK, Levels JH, Peters MJ, Huizer EE, Dijkmans BA, et al. Improvement of lipid profile is accompanied by atheroprotective alterations in high-density lipoprotein composition upon tumor necrosis factor blockade: a prospective cohort study in ankylosing spondylitis. Arthritis Rheum. 2009;60(5):1324–30.PubMedCrossRefGoogle Scholar
  20. 20.
    Tam LS, Shang Q, Kun EW, Lee KL, Yip ML, Li M, et al. The effects of golimumab on subclinical atherosclerosis and arterial stiffness in ankylosing spondylitis-a randomized, placebo-controlled pilot trial. Rheumatology (Oxford). 2014;53(6):1065–74.CrossRefGoogle Scholar
  21. 21.
    Calderaro DC, Ferreira GA. Presentation and prognosis of shrinking lung syndrome in systemic lupus erythematosus: report of four cases. Rheumatol Int. 2012;32(5):1391–6.PubMedCrossRefGoogle Scholar
  22. 22.
    Bilgici A, Ulusoy H, Kuru O, Celenk C, Unsal M, Danaci M. Pulmonary involvement in rheumatoid arthritis. Rheumatol Int. 2005;25(6):429–35.PubMedCrossRefGoogle Scholar
  23. 23.
    Wolfe F, Caplan L, Michaud K. Rheumatoid arthritis treatment and the risk of severe interstitial lung disease. Scand J Rheumatol. 2007;36(3):172–8.PubMedCrossRefGoogle Scholar
  24. 24.
    Pappas DA, Giles JT, Connors G, Lechtzin N, Bathon JM, Danoff SK. Respiratory symptoms and disease characteristics as predictors of pulmonary function abnormalities in patients with rheumatoid arthritis: an observational cohort study. Arthritis Res Ther. 2010;12(3):R104.PubMedPubMedCentralCrossRefGoogle Scholar
  25. 25.
    Kolman J, Morris I. Cricoarytenoid arthritis: a cause of acute upper airway obstruction in rheumatoid arthritis. Can J Anaesth. 2002;49(7):729–32.PubMedCrossRefGoogle Scholar
  26. 26.
    Segebarth PB, Limbird TJ. Perioperative acute upper airway obstruction secondary to severe rheumatoid arthritis. J Arthroplast. 2007;22(6):916–9.CrossRefGoogle Scholar
  27. 27.
    Fabian TC, Hoots AV, Stanford DS, Patterson CR, Mangiante EC. Fat embolism syndrome: prospective evaluation in 92 fracture patients. Crit Care Med. 1990;18(1):42–6.PubMedPubMedCentralCrossRefGoogle Scholar
  28. 28.
    Kauppi M, Neva MH. Sensitivity of lateral view cervical spine radiographs taken in the neutral position in atlantoaxial subluxation in rheumatic diseases. Clin Rheumatol. 1998;17(6):511–4.PubMedCrossRefGoogle Scholar
  29. 29.
    Calvo-Alen J, Toloza SM, Fernandez M, Bastian HM, Fessler BJ, Roseman JM, et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXV. Smoking, older age, disease activity, lupus anticoagulant, and glucocorticoid dose as risk factors for the occurrence of venous thrombosis in lupus patients. Arthritis Rheum. 2005;52(7):2060–8.PubMedCrossRefPubMedCentralGoogle Scholar
  30. 30.
    Ramakrishna G, Sprung J, Ravi BS, Chandrasekaran K, McGoon MD. Impact of pulmonary hypertension on the outcomes of noncardiac surgery: predictors of perioperative morbidity and mortality. J Am Coll Cardiol. 2005;45(10):1691–9.CrossRefGoogle Scholar
  31. 31.
    Aveline C, Leroux A, Vautier P, Cognet F, Le Hetet H, Bonnet F. Risk factors for renal dysfunction after total hip arthroplasty. Ann Fr Anesth Reanim. 2009;28(9):728–34.PubMedCrossRefGoogle Scholar
  32. 32.
    Chen HL, Shen LJ, Hsu PN, Shen CY, Hall SA, Hsiao FY. Cumulative burden of glucocorticoid-related adverse events in patients with systemic lupus erythematosus: findings from a 12-year longitudinal study. J Rheumatol. 2018;45(1):83–9.PubMedCrossRefGoogle Scholar
  33. 33.
    Gladman DD, Urowitz MB, Chaudhry-Ahluwalia V, Hallet DC, Cook RJ. Predictive factors for symptomatic osteonecrosis in patients with systemic lupus erythematosus. J Rheumatol. 2001;28(4):761–5.PubMedPubMedCentralGoogle Scholar
  34. 34.
    Mourao AF, Amaral M, Caetano-Lopes J, Isenberg D. An analysis of joint replacement in patients with systemic lupus erythematosus. Lupus. 2009;18(14):1298–302.PubMedCrossRefGoogle Scholar
  35. 35.
    White SM, Rashid N, Chakladar A. An analysis of renal dysfunction in 1511 patients with fractured neck of femur: the implications for peri-operative analgesia. Anaesthesia. 2009;64(10):1061–5.PubMedCrossRefGoogle Scholar
  36. 36.
    Scanzello CR, Figgie MP, Nestor BJ, Goodman SM. Perioperative management of medications used in the treatment of rheumatoid arthritis. HSS J. 2006;2(2):141–7.PubMedPubMedCentralCrossRefGoogle Scholar
  37. 37.
    Kapetanovic MC, Lindqvist E, Saxne T, Eberhardt K. Orthopaedic surgery in patients with rheumatoid arthritis over 20 years: prevalence and predictive factors of large joint replacement. Ann Rheum Dis. 2008;67(10):1412–6.PubMedCrossRefGoogle Scholar
  38. 38.
    Asai S, Takahashi N, Funahashi K, Yoshioka Y, Takemoto T, Terabe K, et al. Concomitant methotrexate protects against total knee arthroplasty in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors. J Rheumatol. 2015;42(12):2255–60.PubMedCrossRefGoogle Scholar
  39. 39.
    Hyrich KL, Lunt M, Dixon WG, Watson KD, Symmons DP, BSR Biologics Register. Effects of switching between anti-TNF therapies on HAQ response in patients who do not respond to their first anti-TNF drug. Rheumatology (Oxford). 2008;47(7):1000–5.CrossRefGoogle Scholar
  40. 40.
    Lalmohamed A, Vestergaard P, de Boer A, Leufkens HG, van Staa TP, de Vries F. Changes in mortality patterns following total hip or knee arthroplasty over the past two decades: a nationwide cohort study. Arthritis Rheumatol. 2014;66(2):311–8.PubMedCrossRefPubMedCentralGoogle Scholar
  41. 41.
    SooHoo NF, Lieberman JR, Ko CY, Zingmond DS. Factors predicting complication rates following total knee replacement. J Bone Joint Surg Am. 2006;88(3):480–5.PubMedPubMedCentralGoogle Scholar
  42. 42.
    Parvizi J, Mui A, Purtill JJ, Sharkey PF, Hozack WJ, Rothman RH. Total joint arthroplasty: when do fatal or near-fatal complications occur? J Bone Joint Surg Am. 2007;89(1):27–32.Google Scholar
  43. 43.
    Matta F, Singala R, Yaekoub AY, Najjar R, Stein PD. Risk of venous thromboembolism with rheumatoid arthritis. Thromb Haemost. 2009;101(1):134–8.PubMedCrossRefPubMedCentralGoogle Scholar
  44. 44.
    LoVerde ZJ, Mandl LA, Johnson BK, Figgie MP, Boettner F, Lee YY, et al. Rheumatoid arthritis does not increase risk of short-term adverse events after total knee arthroplasty: a retrospective case-control study. J Rheumatol. 2015;42(7):1123–30.PubMedPubMedCentralCrossRefGoogle Scholar
  45. 45.
    Ravi B, Croxford R, Hollands S, Paterson JM, Bogoch E, Kreder H, et al. Increased risk of complications following total joint arthroplasty in patients with rheumatoid arthritis. Arthritis Rheumatol. 2014;66(2):254–63.PubMedCrossRefGoogle Scholar
  46. 46.
    Roman MJ, Devereux RB, Schwartz JE, Lockshin MD, Paget SA, Davis A, et al. Arterial stiffness in chronic inflammatory diseases. Hypertension. 2005;46(1):194–9.PubMedCrossRefPubMedCentralGoogle Scholar
  47. 47.
    Nikiphorou E, Norton S, Young A, Carpenter L, Dixey J, Walsh DA, et al. Association between rheumatoid arthritis disease activity, progression of functional limitation and long-term risk of orthopaedic surgery: combined analysis of two prospective cohorts supports EULAR treat to target DAS thresholds. Ann Rheum Dis. 2016;75(12):2080–6.PubMedPubMedCentralCrossRefGoogle Scholar
  48. 48.
    Devereaux PJ, Xavier D, Pogue J, Guyatt G, Sigamani A, Garutti I, et al. Characteristics and short-term prognosis of perioperative myocardial infarction in patients undergoing noncardiac surgery: a cohort study. Ann Intern Med. 2011;154(8):523–8.PubMedCrossRefPubMedCentralGoogle Scholar
  49. 49.
    Doran MF, Crowson CS, Pond GR, O’Fallon WM, Gabriel SE. Predictors of infection in rheumatoid arthritis. Arthritis Rheum. 2002;46(9):2294–300.PubMedCrossRefGoogle Scholar
  50. 50.
    George MD, Baker JF, Hsu JY, Wu Q, Xie F, Chen L, et al. Perioperative timing of infliximab and the risk of serious infection after elective hip and knee arthroplasty. Arthritis Care Res (Hoboken). 2017;69(12):1845–54.CrossRefGoogle Scholar
  51. 51.
    Goodman SM, Menon I, Christos PJ, Smethurst R, Bykerk VP. Management of perioperative tumour necrosis factor alpha inhibitors in rheumatoid arthritis patients undergoing arthroplasty: a systematic review and meta-analysis. Rheumatology (Oxford). 2016;55(3):573–82.Google Scholar
  52. 52.
    Bongartz T, Nannini C, Medina-Velasquez YF, Achenbach SJ, Crowson CS, Ryu JH, et al. Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study. Arthritis Rheum. 2010;62(6):1583–91.PubMedPubMedCentralCrossRefGoogle Scholar
  53. 53.
    Smetana GW, Lawrence VA, Cornell JE, American College of Physicians. Preoperative pulmonary risk stratification for noncardiothoracic surgery: systematic review for the American College of Physicians. Ann Intern Med. 2006;144(8):581–95.PubMedCrossRefPubMedCentralGoogle Scholar
  54. 54.
    Kauppi M, Laiho K, Neva M. Diagnosing atlantoaxial impaction and basilar invagination. J Bone Joint Surg Am. 2002;84-A(3):491–2.CrossRefGoogle Scholar
  55. 55.
    Neva MH, Isomaki P, Hannonen P, Kauppi M, Krishnan E, Sokka T. Early and extensive erosiveness in peripheral joints predicts atlantoaxial subluxations in patients with rheumatoid arthritis. Arthritis Rheum. 2003;48(7):1808–13.PubMedCrossRefGoogle Scholar
  56. 56.
    Neva MH, Hakkinen A, Makinen H, Hannonen P, Kauppi M, Sokka T. High prevalence of asymptomatic cervical spine subluxation in patients with rheumatoid arthritis waiting for orthopaedic surgery. Ann Rheum Dis. 2006;65(7):884–8.PubMedCrossRefPubMedCentralGoogle Scholar
  57. 57.
    Wolfs JF, Kloppenburg M, Fehlings MG, van Tulder MW, Boers M, Peul WC. Neurologic outcome of surgical and conservative treatment of rheumatoid cervical spine subluxation: a systematic review. Arthritis Rheum. 2009;61(12):1743–52.PubMedCrossRefPubMedCentralGoogle Scholar
  58. 58.
    Sanja MR, Mirjana ZS. Ultrasonographic study of the painful shoulder in patients with rheumatoid arthritis and patients with degenerative shoulder disease. Acta Reumatol Port. 2010;35(1):50–8.PubMedPubMedCentralGoogle Scholar
  59. 59.
    Betts HM, Abu-Rajab R, Nunn T, Brooksbank AJ. Total shoulder replacement in rheumatoid disease: a 16- to 23-year follow-up. J Bone Joint Surg Br. 2009;91(9):1197–200.PubMedCrossRefPubMedCentralGoogle Scholar
  60. 60.
    Rozing PM, Nagels J, Rozing MP. Prognostic factors in arthroplasty in the rheumatoid shoulder. HSS J. 2011;7(1):29–36.PubMedCrossRefGoogle Scholar
  61. 61.
    Hambright D, Henderson RA, Cook C, Worrell T, Moorman CT, Bolognesi MP. A comparison of perioperative outcomes in patients with and without rheumatoid arthritis after receiving a total shoulder replacement arthroplasty. J Shoulder Elb Surg. 2011;20(1):77–85.CrossRefGoogle Scholar
  62. 62.
    Goodman SM, Ramsden-Stein DN, Huang WT, Zhu R, Figgie MP, Alexiades MM, et al. Patients with rheumatoid arthritis are more likely to have pain and poor function after total hip replacements than patients with osteoarthritis. J Rheumatol. 2014;41(9):1774–80.PubMedCrossRefGoogle Scholar
  63. 63.
    Goodman SM, Johnson B, Huang W, Figgie MP, Alexiades M, Mandl LA. Rheumatoid arthritis (RA) patients have similar excellent outcomes after total knee replacement compared with osteoarthritis (OA) patients. AnnRheumDis. 2013;72(Suppl3):586.Google Scholar
  64. 64.
    Rud-Sorensen C, Pedersen AB, Johnsen SP, Riis AH, Overgaard S. Survival of primary total hip arthroplasty in rheumatoid arthritis patients. Acta Orthop. 2010;81(1):60–5.PubMedPubMedCentralCrossRefGoogle Scholar
  65. 65.
    Goodman SM, Mandl LA, Figgie M, Johnson BK, Alexiades M, Ghomrawi H. The use of biologic DMARDs identifies rheumatoid arthritis patients with more optimistic expectations of total knee arthroplasty. HSS J. 2014;10(2):117–23.PubMedPubMedCentralCrossRefGoogle Scholar
  66. 66.
    Oinuma K, Harada Y, Nawata Y, Takabayashi K, Abe I, Kamikawa K, et al. Osteonecrosis in patients with systemic lupus erythematosus develops very early after starting high dose corticosteroid treatment. Ann Rheum Dis. 2001;60(12):1145–8.PubMedPubMedCentralCrossRefGoogle Scholar
  67. 67.
    Gladman DD, Chaudhry-Ahluwalia V, Ibanez D, Bogoch E, Urowitz MB. Outcomes of symptomatic osteonecrosis in 95 patients with systemic lupus erythematosus. J Rheumatol. 2001;28(10):2226–9.PubMedGoogle Scholar
  68. 68.
    Gladman DD, Dhillon N, Su J, Urowitz MB. Osteonecrosis in SLE: prevalence, patterns, outcomes and predictors. Lupus. 2018;27(1):76–81.PubMedCrossRefGoogle Scholar
  69. 69.
    Prasad R, Ibanez D, Gladman D, Urowitz M. The role of non-corticosteroid related factors in osteonecrosis (ON) in systemic lupus erythematosus: a nested case-control study of inception patients. Lupus. 2007;16(3):157–62.PubMedCrossRefGoogle Scholar
  70. 70.
    Agarwala S, Jain D, Joshi VR, Sule A. Efficacy of alendronate, a bisphosphonate, in the treatment of AVN of the hip. A prospective open-label study. Rheumatology (Oxford). 2005;44(3):352–9.CrossRefGoogle Scholar
  71. 71.
    Sun Y, Zhang CQ, Chen SB, Sheng JG, Jin DX, Zeng BF. Treatment of femoral head osteonecrosis in patients with systemic lupus erythematosus by free vascularised fibular grafting. Lupus. 2009;18(12):1061–5.PubMedCrossRefGoogle Scholar
  72. 72.
    Chen YW, Chang JK, Huang KY, Lin GT, Lin SY, Huang CY. Hip arthroplasty for osteonecrosis in patients with systemic lupus erythematosus. Kaohsiung J Med Sci. 1999;15(12):697–703.PubMedGoogle Scholar
  73. 73.
    Salmon JE, Roman MJ. Accelerated atherosclerosis in systemic lupus erythematosus: implications for patient management. Curr Opin Rheumatol. 2001;13(5):341–4.PubMedCrossRefGoogle Scholar
  74. 74.
    Bennet SJ, Berry OM, Goddard J, Keating JF. Acute renal dysfunction following hip fracture. Injury. 2010;41(4):335–8.PubMedCrossRefGoogle Scholar
  75. 75.
    Arora P, Rajagopalam S, Ranjan R, Kolli H, Singh M, Venuto R, et al. Preoperative use of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers is associated with increased risk for acute kidney injury after cardiovascular surgery. Clin J Am Soc Nephrol. 2008;3(5):1266–73.PubMedPubMedCentralCrossRefGoogle Scholar
  76. 76.
    Erkan D, Lockshin MD. Antiphospholipid syndrome. Curr Opin Rheumatol. 2006;18(3):242–8.PubMedGoogle Scholar
  77. 77.
    Erkan D, Leibowitz E, Berman J, Lockshin MD. Perioperative medical management of antiphospholipid syndrome: hospital for special surgery experience, review of literature, and recommendations. J Rheumatol. 2002;29(4):843–9.PubMedGoogle Scholar
  78. 78.
    Kreikemeier J, Tobias JD. Antiphospholipid antibody syndrome manifested as a postoperative cerebrovascular event in a child. South Med J. 2000;93(11):1115–9.PubMedCrossRefGoogle Scholar
  79. 79.
    Reynaud Q, Lega JC, Mismetti P, Chapelle C, Wahl D, Cathebras P, et al. Risk of venous and arterial thrombosis according to type of antiphospholipid antibodies in adults without systemic lupus erythematosus: a systematic review and meta-analysis. Autoimmun Rev. 2014;13(6):595–608.PubMedCrossRefGoogle Scholar
  80. 80.
    Shah UH, Mandl LA, Mertelsmann-Voss C, Lee YY, Alexiades MM, Figgie MP, et al. Systemic lupus erythematosus is not a risk factor for poor outcomes after total hip and total knee arthroplasty. Lupus. 2015;24(9):900–8.PubMedPubMedCentralCrossRefGoogle Scholar
  81. 81.
    Johannson HR, Zywiel MG, Marker DR, Jones LC, McGrath MS, Mont MA. Osteonecrosis is not a predictor of poor outcomes in primary total hip arthroplasty: a systematic literature review. Int Orthop. 2011;35(4):465–73.PubMedCrossRefGoogle Scholar
  82. 82.
    Mont MA, Glueck CJ, Pacheco IH, Wang P, Hungerford DS, Petri M. Risk factors for osteonecrosis in systemic lupus erythematosus. J Rheumatol. 1997;24(4):654–62.PubMedGoogle Scholar
  83. 83.
    Huo MH, Salvati EA, Browne MG, Pellicci PM, Sculco TP, Johanson NA. Primary total hip arthroplasty in systemic lupus erythematosus. J Arthroplast. 1992;7(1):51–6.CrossRefGoogle Scholar
  84. 84.
    Ito H, Matsuno T, Hirayama T, Tanino H, Minami A. Health-related quality of life in patients with systemic lupus erythematosus after medium to long-term follow-up of hip arthroplasty. Lupus. 2007;16(5):318–23.PubMedCrossRefGoogle Scholar
  85. 85.
    Roberts JE, Mandl LA, Su EP, Mayman DJ, Figgie MP, Fein AW, et al. Patients with systemic lupus erythematosus have increased risk of short-term adverse events after total hip arthroplasty. J Rheumatol. 2016;43(8):1498–502.PubMedCrossRefGoogle Scholar
  86. 86.
    Fein AW, Figgie CA, Dodds TR, Wright-Chisem J, Parks ML, Mandl LA, et al. Systemic lupus erythematosus does not increase risk of adverse events in the first 6 months after total knee arthroplasty. J Clin Rheumatol. 2016;22(7):355–9.PubMedCrossRefGoogle Scholar
  87. 87.
    Lin JA, Liao CC, Lee YJ, Wu CH, Huang WQ, Chen TL. Adverse outcomes after major surgery in patients with systemic lupus erythematosus: a nationwide population-based study. Ann Rheum Dis. 2014;73(9):1646–51.PubMedCrossRefGoogle Scholar
  88. 88.
    Zochling J, van der Heijde D, Burgos-Vargas R, Collantes E, Davis JC Jr, Dijkmans B, et al. ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis. 2006;65(4):442–52.PubMedCrossRefGoogle Scholar
  89. 89.
    Chen HA, Chen CH, Liao HT, Lin YJ, Chen PC, Chen WS, et al. Factors associated with radiographic spinal involvement and hip involvement in ankylosing spondylitis. Semin Arthritis Rheum. 2011;40(6):552–8.PubMedCrossRefGoogle Scholar
  90. 90.
    Sochart DH, Porter ML. Long-term results of total hip replacement in young patients who had ankylosing spondylitis. Eighteen to thirty-year results with survivorship analysis. J Bone Joint Surg Am. 1997;79(8):1181–9.PubMedCrossRefGoogle Scholar
  91. 91.
    Sweeney S, Gupta R, Taylor G, Calin A. Total hip arthroplasty in ankylosing spondylitis: outcome in 340 patients. J Rheumatol. 2001;28(8):1862–6.PubMedPubMedCentralGoogle Scholar
  92. 92.
    Parvizi J, Duffy GP, Trousdale RT. Total knee arthroplasty in patients with ankylosing spondylitis. J Bone Joint Surg Am. 2001;83-A(9):1312–6.CrossRefGoogle Scholar
  93. 93.
    van Royen BJ, de Kleuver M, Slot GH. Polysegmental lumbar posterior wedge osteotomies for correction of kyphosis in ankylosing spondylitis. Eur Spine J. 1998;7(2):104–10.PubMedPubMedCentralCrossRefGoogle Scholar
  94. 94.
    Vosse D, Landewe R, van der Heijde D, van der Linden S, van Staa TP, Geusens P. Ankylosing spondylitis and the risk of fracture: results from a large primary care-based nested case-control study. Ann Rheum Dis. 2009;68(12):1839–42.PubMedCrossRefPubMedCentralGoogle Scholar
  95. 95.
    Westerveld LA, Verlaan JJ, Oner FC. Spinal fractures in patients with ankylosing spinal disorders: a systematic review of the literature on treatment, neurological status and complications. Eur Spine J. 2009;18(2):145–56.PubMedCrossRefGoogle Scholar
  96. 96.
    Caron T, Bransford R, Nguyen Q, Agel J, Chapman J, Bellabarba C. Spine fractures in patients with ankylosing spinal disorders. Spine (Phila Pa 1976). 2010;35(11):E458–64.CrossRefGoogle Scholar
  97. 97.
    Iorio R, Healy WL. Heterotopic ossification after hip and knee arthroplasty: risk factors, prevention, and treatment. J Am Acad Orthop Surg. 2002;10(6):409–16.PubMedCrossRefGoogle Scholar
  98. 98.
    Qaseem A, Snow V, Fitterman N, Hornbake ER, Lawrence VA, Smetana GW, et al. Risk assessment for and strategies to reduce perioperative pulmonary complications for patients undergoing noncardiothoracic surgery: a guideline from the American College of Physicians. Ann Intern Med. 2006;144(8):575–80.PubMedCrossRefPubMedCentralGoogle Scholar
  99. 99.
    Kanathur N, Lee-Chiong T. Pulmonary manifestations of ankylosing spondylitis. Clin Chest Med. 2010;31(3):547–54.PubMedCrossRefGoogle Scholar
  100. 100.
    Blouw EL, Rudolph AD, Narr BJ, Sarr MG. The frequency of respiratory failure in patients with morbid obesity undergoing gastric bypass. AANA J. 2003;71(1):45–50.PubMedGoogle Scholar
  101. 101.
    Wright KA, Crowson CS, Michet CJ, Matteson EL. Time trends in incidence, clinical features, and cardiovascular disease in ankylosing spondylitis over three decades: a population-based study. Arthritis Care Res (Hoboken). 2015;67(6):836–41.CrossRefGoogle Scholar
  102. 102.
    Brunner F, Kunz A, Weber U, Kissling R. Ankylosing spondylitis and heart abnormalities: do cardiac conduction disorders, valve regurgitation and diastolic dysfunction occur more often in male patients with diagnosed ankylosing spondylitis for over 15 years than in the normal population? Clin Rheumatol. 2006;25(1):24–9.PubMedCrossRefGoogle Scholar
  103. 103.
    Yildirir A, Aksoyek S, Calguneri M, Oto A, Kes S. Echocardiographic evidence of cardiac involvement in ankylosing spondylitis. Clin Rheumatol. 2002;21(2):129–34.PubMedCrossRefGoogle Scholar
  104. 104.
    Dik VK, Peters MJ, Dijkmans PA, Van der Weijden MA, De Vries MK, Dijkmans BA, et al. The relationship between disease-related characteristics and conduction disturbances in ankylosing spondylitis. Scand J Rheumatol. 2010;39(1):38–41.PubMedCrossRefGoogle Scholar
  105. 105.
    Bremander A, Petersson IF, Bergman S, Englund M. Population-based estimates of common comorbidities and cardiovascular disease in ankylosing spondylitis. Arthritis Care Res (Hoboken). 2011;63(4):550–6.CrossRefGoogle Scholar
  106. 106.
    Muntean L, Rojas-Vargas M, Font P, Simon SP, Rednic S, Schiotis R, et al. Relative value of the lumbar spine and hip bone mineral density and bone turnover markers in men with ankylosing spondylitis. Clin Rheumatol. 2011;30(5):691–5.PubMedCrossRefGoogle Scholar
  107. 107.
    van der Weijden MA, van Denderen JC, Lems WF, Heymans MW, Dijkmans BA, van der Horst-Bruinsma IE. Low bone mineral density is related to male gender and decreased functional capacity in early spondylarthropathies. Clin Rheumatol. 2011;30(4):497–503.PubMedCrossRefGoogle Scholar
  108. 108.
    Arends S, Spoorenberg A, Bruyn GA, Houtman PM, Leijsma MK, Kallenberg CG, et al. The relation between bone mineral density, bone turnover markers, and vitamin D status in ankylosing spondylitis patients with active disease: a cross-sectional analysis. Osteoporos Int. 2011;22(5):1431–9.PubMedCrossRefGoogle Scholar
  109. 109.
    Gladman DD, Chandran V. Observational cohort studies: lessons learnt from the University of Toronto Psoriatic Arthritis Program. Rheumatology (Oxford). 2011;50(1):25–31.CrossRefGoogle Scholar
  110. 110.
    Gladman DD, Shuckett R, Russell ML, Thorne JC, Schachter RK. Psoriatic arthritis (PSA) – an analysis of 220 patients. Q J Med. 1987;62(238):127–41.PubMedGoogle Scholar
  111. 111.
    Gladman DD, Mease PJ, Choy EH, Ritchlin CT, Perdok RJ, Sasso EH. Risk factors for radiographic progression in psoriatic arthritis: subanalysis of the randomized controlled trial ADEPT. Arthritis Res Ther. 2010;12(3):R113.PubMedPubMedCentralCrossRefGoogle Scholar
  112. 112.
    Michet CJ, Mason TG, Mazlumzadeh M. Hip joint disease in psoriatic arthritis: risk factors and natural history. Ann Rheum Dis. 2005;64(7):1068–70.PubMedPubMedCentralCrossRefGoogle Scholar
  113. 113.
    Mandl LA, Zhu R, Huang WT, Zhang M, Alexiades MM, Figgie MP, et al. Short term total hip arthroplasty outcomes in patients with psoriatic arthritis, psoriasis skin disease, and osteoarthritis. Arthritis Rheumatol. 2016;68(2):410–7.PubMedCrossRefGoogle Scholar
  114. 114.
    Buckley C, Cavill C, Taylor G, Kay H, Waldron N, Korendowych E, et al. Mortality in psoriatic arthritis – a single-center study from the UK. J Rheumatol. 2010;37(10):2141–4.PubMedCrossRefGoogle Scholar
  115. 115.
    Tobin AM, Veale DJ, Fitzgerald O, Rogers S, Collins P, O’Shea D, et al. Cardiovascular disease and risk factors in patients with psoriasis and psoriatic arthritis. J Rheumatol. 2010;37(7):1386–94.PubMedCrossRefGoogle Scholar
  116. 116.
    Stern SH, Insall JN, Windsor RE, Inglis AE, Dines DM. Total knee arthroplasty in patients with psoriasis. Clin Orthop Relat Res. 1989;(248):108–10; discussion 111.Google Scholar
  117. 117.
    Beyer CA, Hanssen AD, Lewallen DG, Pittelkow MR. Primary total knee arthroplasty in patients with psoriasis. J Bone Joint Surg Br. 1991;73(2):258–9.PubMedCrossRefGoogle Scholar
  118. 118.
    Zangger P, Esufali ZH, Gladman DD, Bogoch ER. Type and outcome of reconstructive surgery for different patterns of psoriatic arthritis. J Rheumatol. 2000;27(4):967–74.PubMedGoogle Scholar
  119. 119.
    Johnson BK, Goodman SM, Alexiades MM, Figgie MP, Demmer RT, Mandl LA. Patterns and associated risk of perioperative use of anti-tumor necrosis factor in patients with rheumatoid arthritis undergoing total knee replacement. J Rheumatol. 2013;40(5):617–23.PubMedPubMedCentralCrossRefGoogle Scholar
  120. 120.
    Goodman SM, Springer B, Guyatt G, Abdel MP, Dasa V, George M, et al. 2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the perioperative management of antirheumatic medication in patients with rheumatic diseases undergoing elective total hip or total knee arthroplasty. Arthritis Rheumatol. 2017;69(8):1538–51.PubMedCrossRefGoogle Scholar
  121. 121.
    Goodman S, Bykerk V, DiCarlo E, Cummings R, Donlin L, Orange D, et al. Flares in patients with rheumatoid arthritis after total hip and total knee arthroplasty: rates, characteristics, and risk factors. J Rheumatol. 2018;45(5):604–11.PubMedCrossRefGoogle Scholar
  122. 122.
    Bromberg JS, Alfrey EJ, Barker CF, Chavin KD, Dafoe DC, Holland T, et al. Adrenal suppression and steroid supplementation in renal transplant recipients. Transplantation. 1991;51(2):385–90.PubMedCrossRefGoogle Scholar
  123. 123.
    Glowniak JV, Loriaux DL. A double-blind study of perioperative steroid requirements in secondary adrenal insufficiency. Surgery. 1997;121(2):123–9.PubMedCrossRefGoogle Scholar
  124. 124.
    Leopold SS, Casnellie MT, Warme WJ, Dougherty PJ, Wingo ST, Shott S. Endogenous cortisol production in response to knee arthroscopy and total knee arthroplasty. J Bone Joint Surg Am. 2003;85-A(11):2163–7.CrossRefGoogle Scholar
  125. 125.
    Dixon WG, Abrahamowicz M, Beauchamp ME, Ray DW, Bernatsky S, Suissa S, et al. Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case-control analysis. Ann Rheum Dis. 2012;71(7):1128–33.PubMedPubMedCentralCrossRefGoogle Scholar
  126. 126.
    Somayaji R, Barnabe C, Martin L. Risk factors for infection following total joint arthroplasty in rheumatoid arthritis. Open Rheumatol J. 2013;7:119–24.PubMedPubMedCentralCrossRefGoogle Scholar
  127. 127.
    Harpaz R, Ortega-Sanchez I, Seward J. Prevention of herpes zoster: recommendation of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep. 2008;57(05):1–30.Google Scholar
  128. 128.
    Jules-Elysee KM, Lipnitsky JY, Patel N, Anastasian G, Wilfred SE, Urban MK, et al. Use of low-dose steroids in decreasing cytokine release during bilateral total knee replacement. Reg Anesth Pain Med. 2011;36(1):36–40.CrossRefGoogle Scholar
  129. 129.
    Liu X, Liu J, Sun G. Preoperative intravenous glucocorticoids can reduce postoperative acute pain following total knee arthroplasty: a meta-analysis. Medicine (Baltimore). 2017;96(35):e7836.CrossRefGoogle Scholar
  130. 130.
    Jules-Elysee KM, Wilfred SE, Memtsoudis SG, Kim DH, YaDeau JT, Urban MK, et al. Steroid modulation of cytokine release and desmosine levels in bilateral total knee replacement: a prospective, double-blind, randomized controlled trial. J Bone Joint Surg Am. 2012;94(23):2120–7.PubMedCrossRefGoogle Scholar
  131. 131.
    Grennan DM, Gray J, Loudon J, Fear S. Methotrexate and early postoperative complications in patients with rheumatoid arthritis undergoing elective orthopaedic surgery. Ann Rheum Dis. 2001;60(3):214–7.PubMedPubMedCentralCrossRefGoogle Scholar
  132. 132.
    Bongartz T. Elective orthopedic surgery and perioperative DMARD management: many questions, fewer answers, and some opinions. J Rheumatol. 2007;34(4):653–5.PubMedGoogle Scholar
  133. 133.
    Jenks KA, Stamp LK, O’Donnell JL, Savage RL, Chapman PT. Leflunomide-associated infections in rheumatoid arthritis. J Rheumatol. 2007;34(11):2201–3.PubMedGoogle Scholar
  134. 134.
    Mushtaq S, Goodman SM, Scanzello CR. Perioperative management of biologic agents used in treatment of rheumatoid arthritis. Am J Ther. 2011;18(5):426–34.PubMedCrossRefGoogle Scholar
  135. 135.
    Bongartz T, Halligan CS, Osmon DR, Reinalda MS, Bamlet WR, Crowson CS, et al. Incidence and risk factors of prosthetic joint infection after total hip or knee replacement in patients with rheumatoid arthritis. Arthritis Rheum. 2008;59(12):1713–20.PubMedPubMedCentralCrossRefGoogle Scholar
  136. 136.
    Galloway JB, Hyrich KL, Mercer LK, Dixon WG, Fu B, Ustianowski AP, et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford). 2011;50(1):124–31.CrossRefGoogle Scholar
  137. 137.
    Giles JT, Bartlett SJ, Gelber AC, Nanda S, Fontaine K, Ruffing V, et al. Tumor necrosis factor inhibitor therapy and risk of serious postoperative orthopedic infection in rheumatoid arthritis. Arthritis Rheum. 2006;55(2):333–7.PubMedCrossRefGoogle Scholar
  138. 138.
    Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295(19):2275–85.PubMedCrossRefGoogle Scholar
  139. 139.
    den Broeder AA, Creemers MC, Fransen J, de Jong E, de Rooij DJ, Wymenga A, et al. Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti-tumor necrosis factor: a large retrospective study. J Rheumatol. 2007;34(4):689–95.Google Scholar
  140. 140.
    Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DP, et al. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 2006;54(8):2368–76.PubMedCrossRefPubMedCentralGoogle Scholar
  141. 141.
    Boyle DL, Soma K, Hodge J, Kavanaugh A, Mandel D, Mease P, et al. The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis. Ann Rheum Dis. 2015;74(6):1311–6.PubMedCrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Department of Medicine, Hospital for Special SurgeryWeill Cornell MedicineNew YorkUSA

Personalised recommendations